Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, open-label trial of low dose naltrexone for prevention of cervical cancer

Next Previous
Trial Profile

A multicenter, open-label trial of low dose naltrexone for prevention of cervical cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Jun 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naltrexone (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 31 May 2017 According to an Immune Therapeutics media release, The company is ready to submit a New Drug Application (NDA) to the Directorate of Pharmacy and Medicines, the application will include results of four phase II clinical trials and one bridging trial clinical trial.
    • 16 Sep 2016 New trial record
    • 23 Aug 2016 According to an Immune Therapeutics media release, Dr, Frank Taulo from the OBGYN Department of Queen Elizabeth Central Hospital in Blantyre is the Principle Investigator of thsi trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top